Medicare Loophole Leads to Drug Gouging

Regulations passed in 2006 requiring Medicare to cover the cost of certain drugs combined with a 2003 act preventing price negotiations is allowing pharmaceutical companies to charge whatever they want for their medication. The most recent example is with the company Turing Pharmaceuticals and their toxoplasmosis drug, Daraprim. After acquiring the drug in August, CEO Martin Skreli raised the price 5,000 percent, from $13.50 per tablet to $750. More can be read at The Atlantic with Julie Beck.


Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or

What's Your Opinion?

We welcome your comments. Join the discussion and let your voice be heard. All fields are required

Website by Geiger Computers